Autologous and allogeneic cardiac stem cell therapy for cardiovascular diseases

Pharmacological Research

Volumn 127, Issue , 2018, Pages 92-100

  Sanz Ruiz, Ricardo ^a   Fernández Avilés, Francisco ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Allogeneic stem cells; Cardiac stem cells; Cardiosphere derived stem cells; Heart failure; ST segment elevation myocardial infarction

Indexed keywords

ACUTE DISEASE; ALLOGENEIC CARDIAC STEM CELL THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; AUTOLOGOUS CARDIAC STEM CELL THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELLS BY BODY ANATOMY; CLINICAL EFFECTIVENESS; CYTOLOGY; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; ISCHEMIC CARDIOMYOPATHY; MICROVASCULATURE; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; SCAR FORMATION; STEM CELL NICHE; ALLOTRANSPLANTATION; ANIMAL; PROCEDURES; STEM CELL TRANSPLANTATION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 85020403872     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.05.024     Document Type: Review

References (53)

1. Townsend, N., Nichols, M., Scarborough, P., Rayner, M., Cardiovascular disease in Europe–epidemiologicalupdate 2015. Eur. Heart J.(36), 2015, 2696–2705.
2. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133 (2016), 447–454.
3. Terzic, A., Behfar, A., Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc. Med. 26 (2016), 395–404.
4. Nunez Garcia, A., Sanz-Ruiz, R., Fernandez Santos, M.E., Fernandez-Aviles, F., Second-generation stem cells for cardiac repair. World J. Stem Cells 7 (2015), 352–367.
5. Afzal, M.R., Samanta, A., Shah, Z.I., et al. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ. Res. 117 (2015), 558–575.
6. Fisher, S.A., Doree, C., Mathur, A., Martin-Rendon, E., Meta-analysis of cell therapy trials for patients with heart failure. Circ. Res. 116 (2015), 1361–1377.
7. Madonna, R., Van Laake, L.W., Davidson, S.M., et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur. Heart J. 37 (2016), 1789–1798.
8. Nadal-Ginard, B., Ellison, G.M., Torella, D., The cardiac stem cell compartment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult. Stem Cell Res. 13 (2014), 615–630.
9. Bergmann, O., Bhardwaj, R.D., Bernard, S., et al. Evidence for cardiomyocyte renewal in humans. Science 324 (2009), 98–102.
10. Kajstura, J., Rota, M., Cappetta, D., et al. Cardiomyogenesis in the aging and failing human heart. Circulation 126 (2012), 1869–1881.
11. Malliaras, K., Zhang, Y., Seinfeld, J., et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol. Med. 5 (2013), 191–209.
12. Torella, D., Ellison, G.M., Karakikes, I., Nadal-Ginard, B., Resident cardiac stem cells. Cell Mol. Life Sci. 64 (2007), 661–673.
13. Ellison, G.M., Galuppo, V., Vicinanza, C., et al. Cardiac stem and progenitor cell identification: different markers for the same cell?. Front. Biosci. (Schol Ed) 2 (2010), 641–652.
14. Ellison, G.M., Waring, C.D., Vicinanza, C., Torella, D., Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart 98 (2012), 5–10.
15. Beltrami, A.P., Barlucchi, L., Torella, D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114 (2003), 763–776.
16. Nadal-Ginard, B., Kajstura, J., Leri, A., Anversa, P., Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. 92 (2003), 139–150.
17. Ellison, G.M., Vicinanza, C., Smith, A.J., et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 154 (2013), 827–842.
18. Messina, E., De Angelis, L., Frati, G., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95 (2004), 911–921.
19. Li, T.S., Cheng, K., Malliaras, K., et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59 (2012), 942–953.
20. Crisostomo, V., Casado, J.G., Baez-Diaz, C., Blazquez, R., Sanchez-Margallo, F.M., Allogeneic cardiac stem cell administration for acute myocardial infarction. Expert Rev. Cardiovasc. Ther. 13 (2015), 285–299.
21. Menasche, P., Cardiac cell therapy: lessons from clinical trials. J. Mol. Cell Cardiol. 50 (2011), 258–265.
22. Al-Daccak, R., Charron, D., Allogenic benefit in stem cell therapy: cardiac repair and regeneration. Tissue Antigens 86 (2015), 155–162.
23. Hocine, H.R., Costa, H.E., Dam, N., et al. Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci. Rep., 7, 2017, 41125.
24. Lauden, L., Boukouaci, W., Borlado, L.R., et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ. Res. 112 (2013), 451–464.
25. Boukouaci, W., Lauden, L., Siewiera, J., et al. Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence. Cardiovasc. Res. 104 (2014), 290–302.
26. Huang, X.P., Sun, Z., Miyagi, Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122 (2010), 2419–2429.
27. Malliaras, K., Li, T.S., Luthringer, D., et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125 (2012), 100–112.
28. Jansen Of Lorkeers, S.J., Eding, J.E., Vesterinen, H.M., et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ. Res. 116 (2015), 80–86.
29. Hare, J.M., DiFede, D.L., Rieger, A.C., et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J. Am. Coll. Cardiol. 69 (2017), 526–537.
30. Tseliou, E., Pollan, S., Malliaras, K., et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J. Am. Coll. Cardiol. 61 (2013), 1108–1119.
31. Welt, F.G., Gallegos, R., Connell, J., et al. Effect of cardiac stem cells on left-ventricular remodeling in a canine model of chronic myocardial infarction. Circ. Heart Fail. 6 (2013), 99–106.
32. Johnston, P.V., Sasano, T., Mills, K., et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 120 (2009), 1075–1083 (7 p following 1083).
33. Lee, S.T., White, A.J., Matsushita, S., et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J. Am. Coll. Cardiol. 57 (2011), 455–465.
34. Yee, K., Malliaras, K., Kanazawa, H., et al. Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One, 9, 2014, e113805.
35. Bolli, R., Tang, X.L., Sanganalmath, S.K., et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 128 (2013), 122–131.
36. Malliaras, K., Smith, R.R., Kanazawa, H., et al. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 128 (2013), 2764–2775.
37. Crisostomo, V., Baez-Diaz, C., Maestre, J., et al. Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine. J. Transl. Med., 13, 2015, 156.
38. Kanazawa, H., Tseliou, E., Malliaras, K., et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ. Heart Fail. 8 (2015), 322–332.
39. Bolli, R., Chugh, A.R., D'Amario, D., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378 (2011), 1847–1857.
40. Chugh, A.R., Beache, G.M., Loughran, J.H., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 126 (2012), S54–S64.
41. Makkar, R.R., Smith, R.R., Cheng, K., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379 (2012), 895–904.
42. Malliaras, K., Makkar, R.R., Smith, R.R., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J. Am. Coll. Cardiol. 63 (2014), 110–122.
43. Takehara, N., Tsutsumi, Y., Tateishi, K., et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol. 52 (2008), 1858–1865.
44. Chakravarty, T., Makkar, R.R., Ascheim, D.D., et al. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Cell Transplant. 26 (2017), 205–214.
45. Bartunek, J., Behfar, A., Dolatabadi, D., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61 (2013), 2329–2338.
46. Bartunek, J., Davison, B., Sherman, W., et al. Congestive heart failure cardiopoietic regenerative therapy (CHART-1) trial design. Eur. J. Heart Fail. 18 (2016), 160–168.
47. Bartunek, J., Terzic, A., Davison, B.A., et al. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur. Heart J., 2016.
48. Karantalis, V., Suncion-Loescher, V.Y., Bagno, L., et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. J. Am. Coll. Cardiol. 66 (2015), 1990–1999.
49. Williams, A.R., Hatzistergos, K.E., Addicott, B., et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127 (2013), 213–223.
50. Sharma, S., Mishra, R., Bigham, G.E., et al. A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells. Circ. Res. 120 (2017), 816–834.
51. Gallet, R., Dawkins, J., Valle, J., et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur. Heart J. 38 (2017), 201–211.
52. Tokita, Y., Tang, X.L., Li, Q., et al. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ. Res. 119 (2016), 635–651.
53. Reich, H., Tseliou, E., de Couto, G., et al. Repeated transplantation of allogeneic cardiosphere-derived cells boosts therapeutic benefits without immune sensitization in a rat model of myocardial infarction. J. Heart Lung Transplant. 35 (2016), 1348–1357.